ArticleOncology letters2026
Fumarate hydratase-deficient renal cell carcinoma arising in acquired cystic kidney disease in a hemodialysis patient: Diagnostic clues from percutaneous renal mass core needle biopsy: A case report.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 76-year-old male patient with a 30-year history of dialysis presented with persistent fever and hematuria. Computed tomography and magnetic resonance imaging suggested a cyst infection associated with acquired cystic kidney disease. Although cyst drainage was planned, ultrasonography incidentally detected a solid mass within the kidney cyst, prompting a switch from drainage to percutaneous biopsy. Histopathological examination revealed fumarate hydratase-deficient renal cell carcinoma, and nephrectomy was performed. Diagnosis of dialysis-associated renal carcinoma relies on imaging techniques. However, it can be difficult to identify malignant tumors in a polycystic kidney using imaging alone, and pathological confirmation by biopsy is often required. The present report highlights the usefulness of performing needle biopsy for suspected masses using the same method that is used by nephrologists for kidney biopsy in cases in which determining the lesion nature from imaging alone is difficult and in hydratase-deficient renal cell carcinoma arising in acquired cystic kidney disease as a dialysis-associated renal carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.